Institutional Stock Ownership and Shareholders
Wells Fargo & Company (NYSE:WFC.PRY) has 0 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
Largest shareholders include
Wells Fargo & Company (NYSE:WFC.PRY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
4h - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
Related News Stories
To suggest that shares of San Francisco-based Wells Fargo (WFC) have lagged in the past few years could very well be an understatement. Consider that since July of 2015 shares of JPMorgan (JPM) and Bank of America (BAC) have increased by 70% and 72% respectively. Meanwhile, shares of Wells Fargo have actually declined slightly. (4-0)
BB&T Corp, M&T Bank and PNC Financial peaked in late-February, mid-March and are now under “death cross” formations. (6-0)
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Visa (V) and Verizon (VZ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (35-0)
IHS Markit Ltd. (NASDAQ:INFO) Q3 2018 Results Earnings Conference Call September 25, 2018 8:00 AM ET (4-0)
The purpose of this article is to initiate a comparative analysis on exchange-traded funds within the Emerging Market segment. Countries in discussion are Hong Kong, Malaysia, and South Korea. The Malaysia and Hong Kong ETFs are cost efficient options compared to the South Korea one. At the same time, exposure to the financial sector is less in the South Korea ETF relative to both the Malaysia and Hong Kong ETFs. (41-0)
At this weekend's EURETINA 2018, Nightstar Therapeutics presented promising data for its XIRIUS trial for the treatment of X-linked Retinitis Pigmentosa (XLRP). (7-0)
BENGALURU (Sept 25): US stocks were little changed on Tuesday, as higher oil prices lifted energy stocks and banks rose in anticipation of an interest rate hike, but losses in Facebook and chipmakers weighed on the market. (4-0)
NEW YORK, Sept 25 — US stocks were little changed today, as higher oil prices lifted energy stocks and banks rose in anticipation of an interest rate hike, but losses in Facebook and chipmakers weighed on the market. (4-0)
(Reuters) - U.S. stocks were little changed on Tuesday, as higher oil prices lifted energy stocks and banks rose in anticipation of an interest rate hike, but losses in Facebook and chipmakers weighed on the market. (4-0)
JPMorgan (JPM - Free Report) recently announced that seeks to expand in Philadelphia and the Delaware Valley. This is part of its plan to expand into 15-20 new markets. The bank will be opening 50 retail branches and hire around 300 new employees in the region by the end of 2023. Further, JPMorgan will invest $3 billion toward mortgage and small business lending in the area and $5 million to help revitalize Philadelphia's Kensington Avenue neighborhood over the next five years. (5-0)
as of ET